SNY | Ticker Profile - Titan Protect

SNY

Sanofi SA

Health Care · Pharmaceuticals · NASDAQ (ADR)

$45.02

Data: 2026-05-15

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$102.4B

Total market value of the company

Trailing P/E

18.43

Reasonably valued

Forward P/E

8.24

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.0%

Year-over-year revenue change

Profit Margin

16.0%

How much profit the company keeps from each dollar of revenue

ROE

6.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$55.90

+24% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 9 analysts covering this stock

About Sanofi SA

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

https://www.sanofi.com

Country: France Employees: 74,846 Industry: Drug Manufacturers - General

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

16.0% PASS

Debt must be below 33% of total assets

Cash Ratio

6.0% PASS

Interest-bearing cash below 33% of assets

Receivables

0.6% PASS

Receivables below 49% of assets

Revenue Purity

0.3% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$62.24

What our model estimates this business is worth per share

Margin of Safety

27.7%

Trading below fair value — margin of safety exists

Rating

OPPORTUNITY

Overall assessment combining ethics, valuation, and quality

Percentile

99.8th

Ranks in the top 0% of our 13,571 screened universe

Ethical Score

90.8

Valuation Score

90.5

Quality Score

52.3

Combined

N/A

Trading at $43 against a fair value of $62, a 31% discount. Passes all ethical screens. Ranks better than 97% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.155

Positive but modest risk-adjusted returns

Kelly Fraction

0.0032

Marginal edge — very small allocation suggested

Calmar Ratio

0.033

Drawdown risk outweighs the returns — higher risk profile

Annual Return

0.8%

Historical annualised return based on price data

Max Drawdown

-23.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

181

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.28

Very low correlation to market moves

52W High

$53.36

16% below the year high

52W Low

$42.33

6% above the year low

Avg Volume

3,406,000

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

0.4%

Low short interest — limited bearish positioning

Div Yield

5.7%

Annual dividend as a percentage of the share price

EPS (TTM)

$2.33

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.27

Conservative use of debt — low financial risk

Current Ratio

1.01

Adequate but worth monitoring

Quick Ratio

0.20

Like current ratio but excludes inventory — stricter test

Gross Margin

72.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

20.0%

Profit from core operations before interest and tax

Free Cash Flow

$16.7B

Positive — the business generates more cash than it spends

Revenue (TTM)

$47.4B

Total revenue over the last 12 months

Net Income

$4.8B

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$63.00

Target Median

$55.90

Target Low

$51.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go